Quasispecies heterogeneity within the E1/E2 region as a pretreatment variable during pegylated interferon therapy of chronic hepatitis C virus infection.
about
Hepatitis C virus: Promising discoveries and new treatmentsEvidence of structural genomic region recombination in Hepatitis C virusEvidence of recombination in quasispecies populations of a Hepatitis C Virus patient undergoing anti-viral therapyViral Determinants of Resistance to Treatment in Patients with Hepatitis CPlasma chemokine levels correlate with the outcome of antiviral therapy in patients with hepatitis CEvolution of naturally occurring 5'non-coding region variants of Hepatitis C virus in human populations of the South American regionAcute hepatitis C virus infection: A chronic problemHepatitis C Virus Diversity and Evolution in the Full Open-Reading Frame during Antiviral TherapyCorrelation between pre-treatment quasispecies complexity and treatment outcome in chronic HCV genotype 3aGenetic Variability of Hepatitis C Virus before and after Combined Therapy of Interferon plus RibavirinEvidence of Recombination in Intrapatient Populations of Hepatitis C VirusComparative Analysis of Nearly Full-Length Hepatitis C Virus Quasispecies from Patients Experiencing Viral Breakthrough during Antiviral Therapy: Clustered Mutations in Three Functional Genes, E2, NS2, and NS5aInfluence of quasispecies on virological responses and disease severity in patients with chronic hepatitis CThe quasispecies nature and biological implications of the hepatitis C virusGenetic Variability of Hepatitis C Virus (HCV) 5' Untranslated Region in HIV/HCV Coinfected Patients Treated with Pegylated Interferon and RibavirinBaseline prediction of combination therapy outcome in hepatitis C virus 1b infected patients by discriminant analysis using viral and host factorsImpact of interferon-ribavirin treatment on hepatitis C virus (HCV) protease quasispecies diversity in HIV- and HCV-coinfected patients.Pegylated interferon and ribavirin promote early evolution of nonstructural 5A protein in individuals with hepatitis C who demonstrate a response to treatment.Ultradeep pyrosequencing of NS3 to predict response to triple therapy with protease inhibitors in previously treated chronic hepatitis C patients.New insight into HCV E1/E2 region of genotype 4a.Complexity and catalytic efficiency of hepatitis C virus (HCV) NS3 and NS4A protease quasispecies influence responsiveness to treatment with pegylated interferon plus ribavirin in HCV/HIV-coinfected patientsThe Core/E1 domain of hepatitis C virus genotype 4a in Egypt does not contain viral mutations or strains specific for hepatocellular carcinoma.Molecular and contextual markers of hepatitis C virus and drug abuse.Activation of the Ras/Raf/MEK pathway facilitates hepatitis C virus replication via attenuation of the interferon-JAK-STAT pathway.Intrinsic Viral Factors Are the Dominant Determinants of the Hepatitis C Virus Response to Interferon Alpha Treatment in Chimeric Mice.Evaluation of the immunogenicity of liposome encapsulated HVR1 and NS3 regions of genotype 3 HCV, either singly or in combinationSequence diversity of hepatitis C virus: implications for immune control and therapy.Comprehensive cloning of patient-derived 9022-bp amplicons of hepatitis C virus.Resistance mechanisms in HCV: from evolution to intervention.Dynamics of Genotypic Mutations of the Hepatitis B Virus Associated With Long-Term Entecavir Treatment Determined With Ultradeep Pyrosequencing: A Retrospective Observational StudyClinical impact of hepatitis B and C virus envelope glycoproteins.Hepatitis C virus genetic variability and evolution.Divergent quasispecies evolution in de novo hepatitis C virus infection associated with bone marrow transplantation.Susceptibility of treatment-naive hepatitis C virus (HCV) clinical isolates to HCV protease inhibitors.Patterns of longitudinal change in hepatitis C virus neutralization titers correlate with the outcome of peginterferon and ribavirin combination therapy.Enhanced protocol for determining the 3' terminus of hepatitis C virus.Inter-genotypic recombinant hepatitis C virus strains in Japan noted by discrepancies between immunoassay and sequencing.High diversity of hepatitis C viral quasispecies is associated with early virological response in patients undergoing antiviral therapy.Prospects for personalizing antiviral therapy for hepatitis C virus with pharmacogenetics.Hepatitis C virus envelope glycoprotein signatures are associated with treatment failure and modulation of viral entry and neutralization.
P2860
Q27468916-B7EB08F4-4E2B-4FB9-804D-B80B07EA80A8Q27473437-003080CC-386A-4027-A648-876929A0F402Q27477594-CA635E78-6A55-4EF2-AF10-59C9064CD41DQ27478062-6645A6D4-57A4-4820-B7BA-A93FBB02A850Q27480302-BF16E79B-8826-4C29-AC26-532E3B8ABF57Q27481052-20345590-9F58-4BC4-AB1B-32280C806F35Q27485639-FD1FB3DF-612F-4F60-B383-79925D6150D7Q27486013-CEC960C1-CC54-40AE-A044-BFBB05D20946Q27486521-22C1269D-5A7F-465E-B1E8-EC607A659D54Q27486648-BCD6C16C-8D9B-4424-BB99-5AEE81F5E992Q27486806-77774F2B-CFBD-486D-B0A5-A9026FF6C15AQ27486924-15DE8545-AD58-4CAF-972B-5762DA69A6A2Q27488410-673BC583-D323-47F1-AAD5-77F8D44CDE61Q27490497-2F01BC41-D725-4FE6-AE3C-73DF37B38414Q28546960-B99D089E-D27E-4B02-B133-DBCB520FB39FQ33770280-CBD45791-35CE-43FE-A066-1A4C1D9BFA4FQ34075725-B5380C19-212C-4D33-B997-F051746F1BC8Q34182392-6EFDD7BD-2157-444F-8D8D-9F5C7AB5CB64Q34983102-F2EA9833-B044-4146-A7B8-FB19F2126091Q35005196-281296A6-9B58-4D63-9E02-AA584F4A0BABQ35077010-0475BBB4-8A14-4D49-9682-19A0ECA57220Q35552537-7AA4F5D6-0BEF-4C5F-8743-732031876769Q35660841-20C22321-1B7B-4A0B-8F00-2CCCA5BB088BQ35689692-0088EDCA-132E-4211-9561-35224EA34AADQ35893868-FF87E965-3AB0-465E-BB0C-17EB7A9370FFQ35950879-A9E0E45C-43E9-4F49-82FB-B0A3368F7E9AQ36179696-A14EF8B1-6B29-4BDF-87BB-2505AA35376DQ36906524-09C5B9AF-07F5-464C-B0BA-6C431B6671F1Q37228736-8A0548D5-D942-4238-8517-F28443E35B81Q37624126-94EDF64F-DBC5-413F-85D9-50C58C9B8DC8Q38083515-36D72027-994D-47A6-B86B-8BA6FC302C41Q38456906-EAFD2F1B-54CF-422D-945B-91AF23CF9D8DQ38741285-884E694A-F1F2-4EC9-ABF4-DB07522EEAFAQ39653573-0A1EEBF2-DF6F-48C5-AFEE-6397FF457692Q41503166-20264284-BD1B-4BB7-BD31-BC8CD299E5E0Q41868562-C59182CC-9F74-40D0-8F0E-2B81FB9628A9Q42648349-959392F3-F50E-48FA-8496-772411E6115CQ42661814-BA7C42AC-DC99-4136-8B01-74A53CAD5E1CQ42731526-1925A75F-DCC4-4559-B3C6-22348EA08F01Q42988476-C3C6811A-C33C-4023-9B8E-74E219E9AE64
P2860
Quasispecies heterogeneity within the E1/E2 region as a pretreatment variable during pegylated interferon therapy of chronic hepatitis C virus infection.
description
2005 nî lūn-bûn
@nan
2005 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի մարտին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Quasispecies heterogeneity wit ...... c hepatitis C virus infection.
@ast
Quasispecies heterogeneity wit ...... c hepatitis C virus infection.
@en
type
label
Quasispecies heterogeneity wit ...... c hepatitis C virus infection.
@ast
Quasispecies heterogeneity wit ...... c hepatitis C virus infection.
@en
prefLabel
Quasispecies heterogeneity wit ...... c hepatitis C virus infection.
@ast
Quasispecies heterogeneity wit ...... c hepatitis C virus infection.
@en
P2093
P2860
P1433
P1476
Quasispecies heterogeneity wit ...... ic hepatitis C virus infection
@en
P2093
Adrian M Dibisceglie
Deborah A Droll
Edgardo Hembrador
Michael W Nickells
Thomas J Chambers
Tiffany Slater
Xiaofeng Fan
P2860
P304
P356
10.1128/JVI.79.5.3071-3083.2005
P577
2005-03-01T00:00:00Z